A Troubling Reality for Colorectal Cancer Survivors: Polypharmacy and Its Impact
The issue of polypharmacy among colorectal cancer (CRC) survivors in Australia has sparked concern among researchers, highlighting a critical aspect of cancer care that often goes unnoticed. Polypharmacy, the use of multiple medications simultaneously, can lead to adverse events and increased risks, especially in the post-treatment phase.
Unveiling the Polypharmacy Landscape in CRC
A recent Australian study has shed light on the extent of polypharmacy among CRC patients. The research team explored medication use patterns in CRC survivors, focusing on the period from diagnosis to up to five years post-diagnosis. The findings were eye-opening: over 70% of CRC patients experienced polypharmacy at some point during the study, with nearly 50% continuing to face this challenge in the years following their diagnosis.
The Evolution of Medication Use in CRC Patients
The study revealed a dynamic shift in medication use for CRC patients. Following diagnosis and primary treatment, there was an increase in the use of analgesics and psychotropic medications over time. This highlights the unique challenges that arise post-CRC diagnosis, including ongoing neuropathy, pain, and psychological symptoms, which require tailored attention and management.
Exploring Polypharmacy Through Linked Data
Researchers utilized the Medicines Intelligence Data Platform, a comprehensive data collection linked to electronic health records of adults in New South Wales. By linking medical records with dispensing records, hospital admissions data, cancer registry data, and death records, they identified 19,056 adults diagnosed with CRC over a five-year period. The study population was categorized based on the stage of their disease, with varying survival rates.
Polypharmacy Rates Across Disease Stages
Interestingly, the proportion of patients experiencing polypharmacy was similar across different disease stages: 74% in the localized group, 79% in the regional group, and 79% in the metastatic group. This suggests that polypharmacy is a prevalent issue regardless of the stage of CRC.
Dispensing Trends and Risk Factors
The number of medications dispensed per patient increased significantly in the first 12 months following CRC diagnosis. Risk factors for polypharmacy included female gender, age 75 years and older, the presence of comorbidities, and socioeconomic disadvantage. These factors were also associated with an increased likelihood of polypharmacy in the later years post-diagnosis.
A First-of-Its-Kind Study
The researchers emphasized the novelty of their study, being the first to explore polypharmacy specifically in Australians with CRC. The findings underscore the dynamic nature of medication use, with an initial increase in medication dispensing following diagnosis, likely coinciding with primary cancer therapies, before returning to pre-diagnosis levels for most patients.
The Composition of Medications: A Changing Landscape
The study also revealed a shift in the composition of dispensed medications. In the year following diagnosis, there was an increased dispensing of supportive medicines such as antiemetics, painkillers, and antidepressants. Notably, opioids, other analgesics, and antidepressants remained among the most commonly dispensed medications throughout the post-active treatment survivorship period.
The Impact on Quality of Life
For patients treated with curative intent, the high rates of polypharmacy are particularly concerning. It indicates excess morbidity and a compromised quality of life for survivors who have been cured of cancer but continue to face poorer health compared to the general population. This highlights the need for a comprehensive approach to survivorship care, addressing both physical and psychological symptoms.
A Call for Action and Discussion
This study raises important questions: How can we optimize medication management for CRC survivors? What strategies can be implemented to reduce the risks associated with polypharmacy? Share your thoughts and insights in the comments below. Let's spark a conversation and work towards improving the quality of life for CRC survivors.
